---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-014154"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:28:10.287869+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InMed reports Q2 net loss $2.6M, cash $3.5M; board accepts director resignation

## Summary
- Net loss of $2.6M for Q2 FY2025 (Dec 31, 2024), vs $1.5M loss a year ago; GAAP loss per share $3.64.
- Cash and equivalents $3.5M as of Dec 31, 2024; company raised $2.9M in Jan 2025, enough through Q2 2025.
- BayMedica revenue $1.1M (-10% YoY); BayMedica achieved net income of $0.23M (189% improvement).
- Board accepted resignation of director Janet Grove effective Feb 10, 2025, following withheld votes at Dec 2024 AGM.
- R&D expenses $1M (up from $0.6M); pipeline updates: INM-901 (Alzheimer's) and INM-089 (dry AMD).

## SEC filing metadata
- accession: 0001213900-25-014154
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/0001213900-25-014154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/ea0231142-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-014154
- JSON: https://secwatch.observer/filing/0001213900-25-014154.json
- Plain text: https://secwatch.observer/filing/0001213900-25-014154.txt

## Key facts
- Executive change
  Janet Grove resigned as Director at InMed Pharmaceuticals Inc..
  - Action: resigned
  - Role: Director
  source text: On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/0001213900-25-014154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.